By: Stephen M. Hahn, M.D., Commissioner of Food an

By: Stephen M. Hahn, M.D., Commissioner of Food and Drugs, Patrizia Cavazzoni, M.D., Acting Director, Center for Drug Evaluation and Research, and Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

https://www.fda.gov/news-events/fda-voices/up...on-program

When the U.S. Food and Drug Administration learned of the novel coronavirus (COVID-19) and its potentially devastating effects, we acted swiftly to set the regulatory stage for drug and biologics manufacturers to develop products to treat this serious disease.

To meet this urgent need, the FDA created the Coronavirus Treatment Acceleration Program (CTAP) to enable the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) to leverage cross-agency scientific resources and expertise to bear on COVID-19 therapeutic development and review.


Does CYDY know about CTAP not sure I heard Nader talking about this

Is CYDY In CTAP ?

I think I read somewhere that RLFTF was in CTAP
I think I posted that before


https://twitter.com/SteveFDA


Hahn's retweet. https://twitter.com/SteveFDA/status/1297527285235556352?s=20

This has to be about an approval. I am not sure it's us, but it has to be an approval.


Read More: https://investorshangout.com/post/newpost/605...z6VxCwUqZ8

xxx.
xx.
x.